The use of atezolizumab–bevacizumab combination therapy in hepatocellular carcinoma showed a better overall survival rate than using separate therapies for HCC [153], in addition to the reversal of the immunosuppressive tumor microenvironment by combining ICIs with anlotinib, which alters the tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. The gene discussed is CD274; the disease is neoplasm.